First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

STRIDE treatment shows a 14.4% objective response rate and manageable safety profile in 111 patients with poor-prognosis unresectable hepatocellular carcinoma.

• Why it matters: Patients with poor prognostic factors are often excluded from clinical trials, leaving a critical gap in understanding effective treatments for this high-need group.
• What they did: The phase IIIb SIERRA study enrolled 111 adults with uHCC and poor prognostic factors, administering STRIDE until disease progression, toxicity, or withdrawal, and assessed safety and efficacy over a defined period.
• The result: Findings indicate a favorable risk-benefit profile, with a 19.8% incidence of Grade 3/4 adverse events within 6 months and a 14.4% objective response rate, supporting STRIDE’s potential for this underserved population.